相关实验视频
Updated: May 20, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
167
在先进的罕见皮肤癌中绘制抗PD-1疗法的潜力
Clio Dessinioti1, Alexander J Stratigos1
1Skin Cancer and Melanoma Unit, 1st Department of Dermatology, Andreas Sygros Hospital, University of Athens, Greece.
概括
系统性抗PD-1药物对罕见的皮肤癌,如瘤,乳外帕杰特病 (EMPD),皮肤血管瘤 (cAS) 和卡波西肉瘤 (KS) 有望,观察到不同的反应. 需要进一步的研究来制定明确的治疗指南.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 免疫治疗是一种免疫疗法.
背景情况:
- 罕见的皮肤癌,包括附性癌,乳外帕杰特病 (EMPD),皮肤血管瘤 (cAS) 和卡波西肉瘤 (KS),在治疗和管理方面存在独特的挑战.
- 了解瘤特征,如瘤突变负担 (TMB) 和PD-L1表达,对于预测治疗反应至关重要.
- 系统性抗PD-1药物越来越多地被用于这些罕见的皮肤恶性瘤的晚期或耐火病例.
研究的目的:
- 审查在患有晚期罕见皮肤癌的患者中全身抗PD-1药物的疗效.
- 要总结这些瘤类型的局部复发,转移率,瘤突变负担 (TMB) 和PD-L1表达.
- 评估治疗反应,并确定抗PD-1治疗的潜在预测生物标志物.
主要方法:
- 进行了一项文献审查,以确定报告使用全身抗PD-1药物治疗副癌,EMPD,cAS和KS的研究.
- 提取并分析了患者人口统计,瘤组织学,TMB,PD-L1表达,治疗方案和临床结果 (反应率,复发率,转移) 的数据.
- 编制了病例系列和个体患者数据,以评估整体反应率和安全性概况.
主要成果:
- 对抗PD-1药物的反应在各种罕见的皮肤癌中观察到,包括脂质癌,毛孔癌,螺旋腺癌,三癌,EMPD,cAS和KS.
- 瘤突变负担 (TMB) 和PD-L1表达显示出高变异性,并且与治疗反应没有一致的相关性;一些患者尽管TMB低或PD-L1表达不足,但仍有反应.
- 总体来说,人们注意到了令人鼓舞的反应,特别是在先前系统治疗失败的晚期疾病患者中,尽管治疗疗效受到患者数量少和治疗方法多样化的限制.
结论:
- 系统性抗PD-1药物在治疗晚期罕见皮肤癌方面表现出潜在的有效性,为其他选择有限的患者提供治疗选择.
- 预测性生物标志物如TMB和PD-L1表达是可变的,需要进一步研究,以充分理解它们在指导抗PD-1治疗中的作用.
- 需要标准化的临床指导方针,为医生提供明确的建议,以优化在罕见皮肤癌中使用抗PD-1药物,改善患者护理和治疗结果.
相关概念视频
Tumor Immunotherapy
450
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
450
Skin Cancer
3.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
3.0K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

